KALC 2025

Satellite Symposium I (A).
Satellite Symposium I (A).		Room A
Date & Time	November 6 (Thu), 2025, 08:30-09:10
Chair(s)	Young Joo Min (Ulsan Univ., Korea)
Speaker	08:30-09:10 Evolving paradigm of ALK+ mNSCLC patient treatment with Lorlatinib Jang Ho Cho (Gachon Univ., Korea)

Session I (A). Lung cancer and risk factors
Session I (A). Lung cancer and risk factors		Room A
Date & Time	November 6 (Thu), 2025, 09:20-10:20
Chair(s)	Sei-Hoon Yang (Wonkwang Univ., Korea)
Speaker	09:20-09:40 Update on the smoking cessation at lung examination collaboration trials Joo Hun Park (Ajou Univ., Korea) 09:40-10:00 Smoking and lung cancer: An epidemiologic perspective on causality Yongho Jee (Ewha Womans Univ., Korea) 10:00-10:20 Climate change-fueled natural hazards and the impacts on lung cancer care Roselle De Guzman (Manila Central University-FDT Medical Foundation Hospital, Philippines)

Session II (A). Partnering for life: Creating a seamless journey together
Session II (A). Partnering for life: Creating a seamless journey together		Room A
Date & Time	November 6 (Thu), 2025, 10:35-11:35
Chair(s)	Si Yeol Song (Univ. of Ulsan, Korea), Jeong Eun Lee (Chungnam National Univ., Korea)
Speaker	10:35-10:55 Educate, empower, engage: Underscoring the value of continuity of care Thomas Newsom-Davis (Chelsea & Westminster Hospital, UK) 10:55-11:15 Toward timely integration of palliative care: Current status of palliative care and advance care planning in Korea Yu Jung Kim (Seoul National Univ., Korea) 11:15-11:35 The heart of care: Empowering lung cancer patients through oncology nursing support Mary Duffy (Peter MacCallum Cancer Centre, Australia)

Luncheon Symposium I.
Luncheon Symposium I.		Room A+B+C
Date & Time	November 6 (Thu), 2025, 11:50-12:30
Chair(s)	Ji-Youn Han (National Cancer Center, Korea)
Speaker	11:50-12:30 FLAURA2: Advancing first-line therapy for patients with EGFRm NSCLC Gyeong-Won Lee (Gyeongsang National Univ., Korea)

Session III (A). Thymic epithelial tumors: Multidisciplinary approach
Session III (A). Thymic epithelial tumors: Multidisciplinary approach		Room A
Date & Time	November 6 (Thu), 2025, 12:50-13:50
Chair(s)	Jin Mo Goo (Seoul National Univ., Korea), Sung Ho Moon (National Cancer Center, Korea)
Speaker	12:50-13:05 Imaging diagnosis and staging of thymoma Yura Ahn (Univ. of Ulsan, Korea) 13:05-13:20 Histology-driven surgical strategies in thymic epithelial tumors: Lymph node management and extent of resection in early thymoma Jae Kwang Yun (Univ. of Ulsan, Korea) 13:20-13:35 Postoperative radiotherapy in thymic tumors: Recent updates or changes Soo Yoon Sung (The Catholic Univ. of Korea, Korea) 13:35-13:50 Update on systemic therapy in thymic epithelial tumors Seoyoung Lee (Yonsei Univ., Korea)

Plenary Session I
Plenary Session I		Room A+B+C
Date & Time	November 6 (Thu), 2025, 14:10-14:50
Chair(s)	Jin-Hyoung Kang (The Catholic Univ. of Korea, Korea)
Speaker	14:10-14:50 New promises and challenges in the treatment of advanced non-oncogen NSCLC Solange Peters (Centre Hospitalier Universitaire Vaudois, Switzerland)

Session IV (A). The evolving landscape of lung cancer surgery
Session IV (A). The evolving landscape of lung cancer surgery		Room A
Date & Time	November 6 (Thu), 2025, 15:10-16:10
Chair(s)	Deog Gon Cho (The Catholic Univ. of Korea, Korea), Wentao Fang (Shanghai Chest Hospital, Shanghai Jiao Tong Univ., China)
Speaker	15:10-15:25 Wedge resection versus segmentectomy for peripherally-located solid stage IA1–2 NSCLC: Are they oncologically equivalent Chang Young Lee (Yonsei Univ., Korea) 15:25-15:40 Knowledge gaps in segmentectomy: What remains to be Hisashi Saji (Tokyo Medical Univ., Japan) 15:40-15:55 Is surgery more challenging after neoadjuvant chemoimmunotherapy: Myth or Reality? In Kyu Park (Seoul National Univ., Korea) 15:55-16:10 The evolving role of robotic surgery in lung cancer: Toward less invasive or more advanced Hyun Koo Kim (Korea Univ., Korea)

Satellite Symposium II (A).
Satellite Symposium II (A).		Room A
Date & Time	November 6 (Thu), 2025, 16:20-17:00
Chair(s)	Ki Hyeong Lee (Chungbuk National Univ., Korea)
Speaker	16:20-17:00 MARIPOSA: Setting the new standard in EGFR-mutant NSCLC Sun Min Lim (Yonsei Univ., Korea)

Session I (B). Advanced radiation techniques and technologies
Session I (B). Advanced radiation techniques and technologies		Room B
Date & Time	November 6 (Thu), 2025, 09:20-10:20
Chair(s)	Hong-Gyun Wu (Seoul National Univ., Korea), Jiraporn Setakornnukul (Siriraj Hospital, Mahidol Univ., Thailand)
Speaker	09:20-09:35 Physical principles and radiobiological characteristics of particle therapy Yu-Wen Hu (Taipei Veterans General Hospital, Taiwan) 09:35-09:50 Role of particle therapy in early-stage non-small cell lung cancer Masatoshi Nakamura (Univ. of Tsukuba Hospital, Japan) 09:50-10:05 Particle therapy in locally advanced lung cancer: Current evidence and future perspectives Yang-Gun Suh (National Cancer Center, Korea) 10:05-10:20 The integration of immunotherapy and particle therapy Jiraporn Setakornnukul (Siriraj Hospital, Mahidol Univ., Thailand)

Session II (B). Latest trends in biomarker-based precision medicine (Korean Association for the Study of Targeted Therapy)
Session II (B). Latest trends in biomarker-based precision medicine (Korean Association for the Study of Targeted Therapy)		Room B
Date & Time	November 6 (Thu), 2025, 10:35-11:35
Chair(s)	Yoon Soo Chang (Yonsei Univ., Korea), Yasir Y. Elamin (Univ. of Texas MD Anderson Cancer Center, USA)
Speaker	10:35-10:50 Targeted therapy in early stage NSCLC Cheol Kyu Park (Chonnam National Univ., Korea) 10:50-11:05 Circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage NSCLC Rina Hui (Univ. of Hong Kong, China) 11:05-11:20 Longitudinal tracking of ALK-rearranged NSCLC from plasma using circulating tumor RNA and circulating tumor DNA Yasir Y. Elamin (Univ. of Texas MD Anderson Cancer Center, USA) 11:20-11:35 The current landscape of liquid biopsy in Korea Eun Hye Lee (Yonsei Univ., Korea)

Session III (B). ADCs: Current controversies
Session III (B). ADCs: Current controversies		Room B
Date & Time	November 6 (Thu), 2025, 12:50-13:50
Chair(s)	Jin Seok Ahn (Sungkyunkwan Univ., Korea), David Planchard (Gustave Roussy Cancer Campus, France)
Speaker	12:50-13:05 The era of antibody drug conjugates in lung cancer: Trick or Threat? David Planchard (Gustave Roussy Cancer Campus, France) 13:05-13:20 Trop2 ADCs: Is there hope or is all is lost? Stephanie Saw (National Cancer Centre Singapore, Singapore) 13:20-13:35 Biomarkers for ADCs: IHC and beyond Jii Bum Lee (Yonsei Univ., Korea) 13:35-13:50 Emerging ADCs: The next generation Molly Li (The Chinese Univ. of Hong Kong, China)

Session IV (B). Oncogene Addicted NSCLC: Beyond EGFR and ALK
Session IV (B). Oncogene Addicted NSCLC: Beyond EGFR and ALK		Room B
Date & Time	November 6 (Thu), 2025, 15:10-16:10
Chair(s)	Tae Min Kim (Seoul National Univ., Korea), Ross Soo (National University Hospital, Singapore)
Speaker	15:10-15:30 For ROS1 Fusion NSCLC, Is there still a place for sequential treatment starting with crizotinib? Aaron Tan (National Cancer Centre Singapore, Singapore) 15:30-15:50 HER2 mutant NSCLC: ADC vs TKI, challenges Ross Soo (National University Hospital, Singapore) 15:50-16:10 KRAS G12C and non-G12C KRAS in lung cancer Min Hee Hong (Yonsei Univ., Korea)

Satellite Symposium II (B).
Satellite Symposium II (B).		Room B
Date & Time	November 6 (Thu), 2025, 16:20-17:00
Chair(s)	Sang-We Kim (Univ. of Ulsan, Korea)
Speaker	16:20-17:00 Surgical game changer: Perioperative immunotherapy in resectable NSCLC Jae Kwang Yun (Univ. of Ulsan, Korea)

Satellite Symposium I (C).
Satellite Symposium I (C).		Room C
Date & Time	November 6 (Thu), 2025, 08:30-09:10
Chair(s)	Taewon Jang (Kosin Univ., Korea)
Speaker	08:30-09:10 Advancing SCLC management with Lurbinectedin clinical experience and IMforte study innovations Jacob Sands (Dana Farber Cancer Institute, USA)

Session I (C). Controversies and future directions of lung cancer screening
Session I (C). Controversies and future directions of lung cancer screening		Room C
Date & Time	November 6 (Thu), 2025, 09:20-10:20
Chair(s)	Yeol Kim (National Cancer Center, Korea), Pan-Chyr Yang (National Taiwan University College of Medicine, Taiwan)
Speaker	09:20-09:35 Optimizing screening eligibility with risk-prediction models and biomarkers Yeon Wook Kim (Seoul National Univ., Korea) 09:35-09:50 Enhancing benefits by increasing uptake and adherenc Roger Y Kim (Univ. of Pennsylvania, USA) 09:50-10:05 Addressing loco-regional specific needs and feasibility of screening in Asia Pan-Chyr Yang (National Taiwan University College of Medicine, Taiwan) 10:05-10:20 Lung cancer screening in never smokers: Radiology perspectives Yeun-Chung Chang (National Taiwan University College of Medicine, Taiwan)

Session II (C). Nodule management and early diagnostic strategies
Session II (C). Nodule management and early diagnostic strategies		Room C
Date & Time	November 6 (Thu), 2025, 10:35-11:35
Chair(s)	Seung Hun Jang (Hallym Univ., Korea), Jianye Chen (National University Hospital, Singapore)
Speaker	10:35-10:50 Novel technologies for nodule risk stratification Young Sik Park (Seoul National Univ., Korea) 10:50-11:05 Advanced bronchoscopy as a modality of choice for peripheral lung lesions Fabien Maldonado (Vanderbilt Univ., USA) 11:05-11:20 Management of multifocal lung adenocarcinomas presenting as GGOs with sub-solid changes Jianye Chen (National University Hospital, Singapore) 11:20-11:35 Advancing lung cancer screening: Detection and management of early-stage lung cancer Jacob Sands (Dana Farber Cancer Institute, USA)

Session III (C). Interventional pulmonology
Session III (C). Interventional pulmonology		Room C
Date & Time	November 6 (Thu), 2025, 12:50-13:50
Chair(s)	Young Sik Park (Seoul National Univ., Korea), Masahide Oki (Nagoya Medical Center, Japan)
Speaker	12:50-13:10 Optimizing tissue acquisition with advanced biopsy techniques Dongil Park (Chungnam Univ., Korea) 13:10-13:30 Bronchoscopic intervention for central airway obstruction due to lung cancer Masahide Oki (Nagoya Medical Center, Japan) 13:30-13:50 Management of malignant pleural effusion: From palliation to treatment David Feller-Kopman (Dartmouth Univ., USA)

Session IV (C). Oral Presentation I
Session IV (C). Oral Presentation I		Room C
Date & Time	November 6 (Thu), 2025, 15:10-16:10
Chair(s)	Sunhee Chang (Inje Univ., Korea), Hak Ryul Kim (Wonkwang Univ., Korea)
Speaker	15:10-15:20 Spatial characterization of immunosuppressive microenvironment in patients with PD-L1 Discordant response to pembrolizumab in advanced non-small cell lung cancer Seong-Eun Kim (Asan Medical Center, Korea) 15:20-15:30 Delta-like ligand 3 (DLL3)-based enrichment enables sensitive and specific detection of circulating tumor cells during immunotherapy in small-cell lung cancer Hyung-Joo Oh (Chonnam National Univ., Korea) 15:30-15:40 Cereblon (CRBN) suppresses lung adenocarcinoma cell migration and invasion by facilitating the degradation of cystathionine beta-synthase (CBS) Hyeon-Seung Yoon (Gwangju Institute of Science and Technology, Korea) 15:40-15:50 Ganoderic acid-chitosan lipid nanoparticles attenuate benzopyrene-induced lung cancer via alteration of PI3K/Akt/mTOR, NF-kB and MAPK/ERK signaling pathway Vikas Kumar (Sam Higginbottom Univ. of Agriculture, Technology & Sciences, India) 15:50-16:00 In vivo CRISPR activation screens reveal drivers of chemoresistance in small cell lung cancer Jae Heun Chung (Pusan National Univ., Korea)

Satellite Symposium II (C).
Satellite Symposium II (C).		Room C
Date & Time	November 6 (Thu), 2025, 16:20-17:00
Chair(s)	Myung-Ju Ahn (Sungkyunkwan Univ., Korea)
Speaker	16:20-17:00 Extending lives, expanding hopes: Tarlatamab in 3L SCLC treatment Jacob Sands (Dana Farber Cancer Institute, USA)

Satellite Symposium III (A).
Satellite Symposium III (A).		Room A
Date & Time	November 7 (Fri), 2025, 08:20-09:00
Chair(s)	Chan Kwon Park (The Catholic Univ. of Korea, Korea)
Speaker	08:20-09:00 From evidence to practice: Brigatinib in the evolving landscape of ALK-Positive NSCLC Jinyong Kim (Sungkyunkwan Univ., Korea)

Session V (A). Novel immunotherapies beyond the PD1 pathway
Session V (A). Novel immunotherapies beyond the PD1 pathway		Room A
Date & Time	November 7 (Fri), 2025, 09:10-10:10
Chair(s)	Dong-Wan Kim (Seoul National Univ., Korea), Aaron Elliott Lisberg (Univ. of California, USA)
Speaker	09:10-09:25 Beyond PD-L1 axis inhibition: Where are we going? Aaron Elliott Lisberg (Univ. of California, USA) 09:25-09:40 Bispecifics and T cell engagers: Fighting against immune desert Jeongmin Seo (Seoul National Univ., Korea) 09:40-09:55 Combining ICIs with ADCs is the way to go? Sun Min Lim (Yonsei Univ., Korea) 09:55-10:10 Cellular therapies: Breaking the glass ceiling Ben Creelan (H. Lee Moffitt Cancer Center & Research Institute, USA)

Session VI (A). Challenges during immunotherapy
Session VI (A). Challenges during immunotherapy		Room A
Date & Time	November 7 (Fri), 2025, 10:25-11:25
Chair(s)	Jae Cheol Lee (Univ. of Ulsan, Korea), Jordi Remon Masip (Institut Gustave Roussy, France)
Speaker	10:25-10:40 Should we exclude immunotherapy in case of advanced NSCLC with oncoge addiction? Jordi Remon Masip (Institut Gustave Roussy, France) 10:40-10:55 When can or should anti-PD(L)-1 be stopped in advanced NSCLC? Jun Hyeok Lim (Inha Univ., Korea) 10:55-11:10 Is it feasible to restart immunotherapy after severe immune-related toxicity? Jinyong Kim (Sungkyunkwan Univ., Korea) 11:10-11:25 Immunotherapy and brain metastases Thomas John (Peter MacCallum Cancer Centre, Australia)

Luncheon Symposium II.
Luncheon Symposium II.		Room A+B+C
Date & Time	November 7 (Fri), 2025, 11:40-12:20
Chair(s)	Young Chul Kim (Chonnam National Univ., Korea)
Speaker	11:40-12:20 What is the future of EGFR-mutant NSCLC treatment: Going solo or combining forces? Se-Hoon Lee (Sungkyunkwan Univ., Korea)

Plenary Session II
Plenary Session II		Room A+B+C
Date & Time	November 7 (Fri), 2025, 12:50-13:30
Chair(s)	Myung-Ju Ahn (Sungkyunkwan Univ., Korea)
Speaker	12:50-13:30 Current uses and pitfalls of liquid biopsy in NSCLC Natasha Leighl (Princess Margaret Cancer Centre, Canada)

Session VII (A). Surgery in the chemoimmunotherapy era: Global perspectives
Session VII (A). Surgery in the chemoimmunotherapy era: Global perspectives		Room A
Date & Time	November 7 (Fri), 2025, 13:50-14:50
Chair(s)	Suk Ki Cho (Seoul National Univ., Korea), Alessandro Brunelli (St. James's University Hospital, UK)
Speaker	13:50-14:05 Refining surgical boundaries after neoadjuvant therapy in lung cance Samina Park (Seoul National Univ., Korea) 14:05-14:20 Optimal nodal management strategies after induction therapy: Scope, challenges, and surgical precision Mong-Wei Lin (National Taiwan University Hospital, Taiwan) 14:20-14:35 Managing pCR in lung cancer: The evolving role of ctDNA in postoperative strategy Jeonghwan Youk (Seoul National Univ., Korea) 14:35-14:50 Real-world surgical outcomes after neoadjuvant chemoimmunotherapy: The European experience Alessandro Brunelli (St. James's University Hospital, UK)

Session VIII (A). Stage-Specific considerations and dilemmas
Session VIII (A). Stage-Specific considerations and dilemmas		Room A
Date & Time	November 7 (Fri), 2025, 15:05-16:05
Chair(s)	Gong Yong Jin (Jeonbuk National Univ., Korea), Jong Ho Cho (Sungkyunkwan Univ., Korea)
Speaker	15:05-15:25 Imaging controversies in lung cancer staging Won Gi Jeong (Chonnam National Univ., Korea) 15:25-15:45 Systematic EBUS Staging to guide therapy June Hong Ahn (Yeungnam Univ., Korea) 15:45-16:05 Should yp-staging be defined in future editions of the TNM classification system? Young Tae Kim (Seoul National Univ., Korea)

Closing Symposium.
Closing Symposium.		Room A
Date & Time	November 7 (Fri), 2025, 16:05-16:45
Chair(s)	Jin-Hyoung Kang (The Catholic Univ. of Korea, Korea)
Speaker	16:05-16:45 Perioperative immunotherapy, better outcomes: The emerging standard of care in resectable NSCLC Hye Ryun Kim (Yonsei Univ., Korea)

Session V (B). Insights into lung cancer pathology
Session V (B). Insights into lung cancer pathology		Room B
Date & Time	November 7 (Fri), 2025, 09:10-10:10
Chair(s)	Jin-Haeng Chung (Seoul National Univ., Korea), Mari Mino-Kenudson (Massachusetts General Hospital, USA)
Speaker	09:10-09:30 Intraoperative evaluations of surgical margins/STAS Mari Mino-Kenudson (Massachusetts General Hospital, USA) 09:30-09:50 Pitfalls in intraoperative evaluations: Benign versus malignant Dong Hoon Shin (Pusan National Univ., Korea) 09:50-10:10 Tissue is the issue: Maximizing molecular insights from small biopsy and cytology samples Yeoun Eun Sung (The Catholic Univ. of Korea, Korea)

Session VI (B). Unlocking lung cancer: Biological discoveries
Session VI (B). Unlocking lung cancer: Biological discoveries		Room B
Date & Time	November 7 (Fri), 2025, 10:25-11:25
Chair(s)	In-Jae Oh (Chonnam National Univ., Korea), Hyo Sup Shim (Yonsei Univ., Korea)
Speaker	10:25-10:40 Decoding systemic inflammation in lung cancer: Toward precision immuno-oncology Jae-Ho Cho (B, Korea) 10:40-10:55 Integrative proteogenomics identifies non-small cell lung cancer subtypes associated with chromosomal instability and enhanced kinase activity Joon-Yong An (Korea Univ., Korea) 10:55-11:10 Lepidic adenocarcinoma emerges from alveolar type 1 cells: Rethinking tumorigenesis and clinical implications Jung-Ki Yoon (Seoul National Univ., Korea) 11:10-11:25 Application of lung cancer organoids in precision medicine Jinwook Choi (GIST, Korea)

Session VII (B). Biology and novel agents in SCLC
Session VII (B). Biology and novel agents in SCLC		Room B
Date & Time	November 7 (Fri), 2025, 13:50-14:50
Chair(s)	Hye Ryun Kim (Yonsei Univ., Korea), Wei-Hsun Hsu (National Taiwan Univ., Taiwan)
Speaker	13:50-14:05 Recent developments in genomics and translational research of SCLC Esra Akbay (Univ. of Texas Southwestern Medical Center, USA) 14:05-14:20 Rewiring a cold tumor: Immunotherapy strategies for every stage of SCLC in 2025 Wei-Hsun Hsu (National Taiwan Univ., Taiwan) 14:20-14:35 Rethinking radiotherapy in the era of new standards for SCLC Young Seob Shin (Univ. of Ulsan, Korea) 14:35-14:50 New drugs in development for SCLC: In search of new hope Se Hyun Kim (Se Hyun Kim, Korea)

Session VIII (B). Decoding the tumor microenvironment: A high-tech revolution
Session VIII (B). Decoding the tumor microenvironment: A high-tech revolution		Room B
Date & Time	November 7 (Fri), 2025, 15:05-16:05
Chair(s)	Byoung Chul Cho (Yonsei Univ., Korea), Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea)
Speaker	15:05-15:20 Latest trend in Multiplex IHC technology for TME research Gil-Je Lee (Akoya biosciences, Inc, Korea) 15:20-15:35 Spatial transcriptomic landscape of NSCLC Yoon Kyung Jwon (Seoul National Univ., Korea) 15:35-15:50 Predicting the TME composition and therapeutic responses using multi-omic technology Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea) 15:50-16:05 Integrative single-cell and spatial analyses to understand the generality and specificity of tumor microenvironment Jong-Eun Park (KAIST, Korea)

Satellite Symposium III (C).
Satellite Symposium III (C).		Room C
Date & Time	November 7 (Fri), 2025, 08:20-09:00
Chair(s)	Ji-Youn Han (National Cancer Center, Korea)
Speaker	08:20-09:00 ENHERTU: The first HER2-targeted ADC for HER2-mutant metastatic NSCLC Jung Seop Eom (Pusan National Univ., Korea)

Session V (C). Oral Presentation II
Session V (C). Oral Presentation II		Room C
Date & Time	November 7 (Fri), 2025, 09:10-10:00
Chair(s)	Sang-Won Um (Sungkyunkwan Univ., Korea), Jae Hyun Jeon (Seoul National Univ., Korea)
Speaker	09:10-09:20 Impact of quitting smoking at diagnosis on overall survival in lung cancer patients: A comprehensive meta-analysis Dongwon Park (Hanyang Univ., Korea) 09:20-09:30 Transbronchial mediastinal cryobiopsy for mediastinal lesions: The first single-center experience in South Korea Min Jee Kim (Asan Medical Center, Korea) 09:30-09:40 Combining deep learning radiomics with clinical data for preoperative prediction of STAS in stage IA lung adenocarcinoma: A multicenter study Xiaocui Liu (Union Hospital, Tongji Medical College, Huazhong Univ. of Science and Technology, China) 09:40-09:50 Exosome-based BALF liquid biopsy(ExoBAL)-guided pre-operative lazertinib therapy in potentially resectable EGFR-mutant tumors In Ae Kim (Konkuk Univ., Korea) 09:50-10:00 Localized defense programs underlie prognostic divergence in GGO and solid lung adenocarcinoma Sanghyun Han (Chungbuk National Univ., Korea)

Session VI (C). Oral Presentation III
Session VI (C). Oral Presentation III		Room C
Date & Time	November 7 (Fri), 2025, 10:25-11:25
Chair(s)	Seong Hoon Yoon (Pusan National Univ, Korea), Gyeong-Won Lee (Gyeongsang National Univ., Korea)
Speaker	10:25-10:35 Effectiveness and radiation pneumonitis of stereotactic body radiation therapy in high-risk patients with early-stage non-small cell lung Yoo Kyung Choi (The Catholic Univ. of Korea, Korea) 10:35-10:45 Identification of a novel Golgi Apparatus signature to prognostic stratification and integrative analyses in lung adenocarcinoma Haoran Li (Sichuan Cancer Hospital, China) 10:45-10:55 Deep learning-driven reconstruction of lineage and immune plasticity trajectories in small cell lung cancer using multi-omics data integration Rifaldy Fajar (The Integrated Mathematical, Computational, and Data Science for Biomedicine Research Foundation, Indonesia) 10:55-11:05 Tislelizumab vs Pembrolizumab for first-line treatment of non-small cell lung cancer: Literature review of indirect treatment comparisons Ji-Youn Han (National Cancer Center, Korea) 11:05-11:15 Predictive value of inflammatory biomarkers in EGFR-mutant NSCLC treated with lazertinib: An interim analysis of a prospective real-world study (ORIENT) Seung Hyeun Lee (Kyung Hee Univ., Korea) 11:15-11:25 Integrated gene expression and network analysis identifies key pathways in small cell lung cancer Nadyatul Husna (Universitas Andalas, Dr. Reksodiwiryo Military Hospital Padang, Indonesia)

Session VII (C). EGFR-Mutant NSCLC: Optimal regimen & rationale
Session VII (C). EGFR-Mutant NSCLC: Optimal regimen & rationale		Room C
Date & Time	November 7 (Fri), 2025, 13:50-14:50
Chair(s)	Jeong-Seon Ryu (Inha Univ., Korea), Grace Dy (Rose Well Park Cancer Institute, USA)
Speaker	13:50-14:05 Mono or Combi, is two really better than one? Derek De-Rui Huang (National Taiwan University, Taiwan) 14:05-14:20 What should we combine with EGFR Tyrosine Kinase Inhibitors(TKIs): Chemotherapy, antibody or Antibody-Drug Conjugates (ADCs) Grace Dy (Rose Well Park Cancer Institute, USA) 14:20-14:35 What is the best sequence for EGFR-Mutant NSCLC? Current options to future options Lyudmila A. Bazhenova (University of California San Diego, USA) 14:35-14:50 Any new treatment options under development in EGFR-Mutant NSCLC currently not approved? Byoung Chul Cho (Yonsei Univ., Korea)

Session VIII (C). Multi-omics and AI-driven precision in lung cancer
Session VIII (C). Multi-omics and AI-driven precision in lung cancer		Room C
Date & Time	November 7 (Fri), 2025, 15:05-16:05
Chair(s)	Ho Yun Lee (Sungkyunkwan Univ., Korea), Sung Yong Lee (Korea Univ., Korea)
Speaker	15:05-15:20 Recent advances in multimodal and multi-omics biomedical AI for precision oncology Chan-Young Ock (Lunit, Korea) 15:20-15:35 Multi-omics-based subtyping of NSCLC Hee Sang Hwang (Univ. of Ulsan, Korea) 15:35-15:50 Multi-omics analysis for discovering therapeutic targets in lung cancer Ken Asada (National Cancer Center Research Institute, Japan) 15:50-16:05 LLMs under the microscope: Using it right in medical research and practice Seong Ho Park (National Cancer Center Research Institute, Korea)

Joint Symposium with HIRA (Korean) - 가이드라인과 급여기준
Joint Symposium with HIRA (Korean) - 가이드라인과 급여기준		Room D
Date & Time	November 7 (Fri), 2025, 09:10-10:25
Chair(s)	이세훈 (성균관의대, Korea), 박인규 (서울의대, Korea)
Speaker	09:10-09:30 폐암 가이드라인에 나타난 새로운 치료법 이윤규 (성균관의대, Korea) 09:30-09:50 폐암 가이드라인에 나타난 새로운 진단법 김태정 (가톨릭의대, Korea) 09:50-10:10 최신 치료법이 건강보험에 반영되는 과정 및 가이드라인의 의미 김국희 (건강보험심사평가원, Korea) 10:10-10:25 패널 토의: 발전적인 급여 등재 과정을 위한 학회와 심평원의 제언 및 논의 이윤규 (성균관의대, Korea), 김태정 (가톨릭의대, Korea), 김국희 (건강보험심사평가원, Korea)

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0125	15:10-15:20	Spatial Characterization of Immunosuppressive Microenvironment in Patients with PD-L1 Discordant Response to Pembrolizumab in Advanced Non-small Cell Lung Cancer	Seong-Eun Kim	Asan Medical Center	Korea
A-0115	15:20-15:30	Delta-like Ligand 3 (DLL3)-based Enrichment Enables Sensitive and Specific Detection of Circulating Tumor Cells During Immunotherapy in Small-cell Lung Cancer	Hyung-Joo Oh	Chonnam National University Medical School and Hwasun Hospital	Korea
A-0088	15:30-15:40	Cereblon (CRBN) Suppresses Lung Adenocarcinoma Cell Migration and Invasion by Facilitating the Degradation of Cystathionine Beta-Synthase (CBS)	Hyeon-Seung Yoon	Gwangju Institute Of Science And Technology	Korea
A-0022	15:40-15:50	In Vivo CRISPR Activation Screens Reveal Drivers of Chemoresistance in Small Cell Lung Cancer	Jae Heun Chung	Pusan National University Yangsan Hospital	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0103	09:10-09:20	Impact of Quitting Smoking at Diagnosis on Overall Survival in Lung Cancer Patients: A Comprehensive Meta-Analysis	Dongwon Park	Hanyang University Medical Center	Korea
A-0151	09:20-09:30	Transbronchial Mediastinal Cryobiopsy for Mediastinal Lesions: The First Single-Center Experience in South Korea	Min Jee Kim	Asan Medical Center	Korea
A-0021	09:30-09:40	Combining Deep Learning Radiomics with Clinical Data for Preoperative Prediction of STAS in Stage IA Lung Adenocarcinoma: a Multicenter Study	Xiaocui Liu	Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology	China
A-0222	09:40-09:50	Exosome-based BALF liquid biopsy(ExoBAL)-guided pre-operative lazertinib therapy in potentially resectable EGFR-mutant tumors	In Ae Kim	Konkuk University Medical Center	Korea
A-0099	09:50-10:00	Localized Defense Programs Underlie Prognostic Divergence in GGO and Solid Lung Adenocarcinoma	Han Sanghyun	Chungbuk National University Hospital	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Clinical Relevance of Pleural Tissue Debris Incidentally Obtained During Catheter Drainage for Pleural Effusion	Jiwon Kim	Kyung Hee University Medical Center	Korea
A-0189	PE1-02	A Radiomics-based Nomogram for Preoperative Prediction of Pathological Subtypes in Nodular Lung Adenocarcinoma: a Multicenter Study	Xiaocui Liu	Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology	China
A-0161	PE1-03	Dual Modulation of Redox and Immune Signaling in Lung Cancer via Pharmacoinformatic Study of Benzothiazepine-Based Immunomodulators Targeting Nrf2 and JAK2-JH1	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0131	PE1-04	Molecular Adaptation Reveals Metabolic and Stress Response Bypass Pathways in Erlotinib-Resistant Non-Small Cell Lung Cancer Subclones	Nadyatul Husna	Universitas Andalas/ Dr. Reksodiwiryo Military Hospital Padang	Indonesia
A-0118	PE1-05	Uncovering Multi-Layered Resistance Mechanisms to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer	Nadyatul Husna	Universitas Andalas/ Dr. Reksodiwiryo Military Hospital Padang	Indonesia
A-0093	PE1-06	Natural Triterpenoids of Peronema canescens as Dual Inhibitors of AKT1 and ERK1/2: A Structure-Based Approach for Overcoming Lung Cancer	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0076	PE1-07	Development of a Novel Inhibitor Against nRAS-Mutated Lung Cancers.	Vikas Kumar	Aiims New Delhi	India
A-0059	PE1-08	Solid Lipid Nanoparticle of Ganodric acid ameliorate benzopyrene induced lung cancer in rats Via Alteration of Nrf2/HO-1 Signaling pathway	V Kumar	Shalom Institute Of Health & Allied Sciences	India
A-0236	PE1-09	Decoding the Role of myomiR-206 in Lung Cancer Cachexia and Its Correlation with IL-6 Signaling	Divo Helmizar	Stan / Perbendaharaan Negara	Indonesia
A-0233	PE1-10	Decoding Hematologic Paraneoplastic Syndromes in Lung Cancer: A Critical Approach to Early Diagnosis	Aryofri Afan	Andalas University	Indonesia
A-0220	PE1-11	Establishment of a Lung Organoid Library from Diverse Clinical Samples for Advanced Disease Modeling	Joo-Eun Lee	Chungnam National University Hospital	Korea
A-0208	PE1-12	Role of PFKFB3 in Maintaining Redox Homeostasis and DNA Integrity in Non-Small Cell Lung Cancer Cells Treated with EGFR-TKIs	Brijalkumar Patel	Gmers Medical College	India
A-0207	PE1-13	Follicular lymphoma presenting with solitary pulmonary nodule: two case reports	Heae Surng Park	Ewha Womans University Medical Center	Korea
A-0181	PE1-14	Nutritional and Lifestyle Interventions in Lung Cancer Prevention and Survivorship in Indonesia	Helen Try Juniasti	Cendrawasih University	Indonesia
A-0174	PE1-15	Enhancing Quality of Life in Lung Cancer Patients: Integrating Palliative Care with Immunotherapy and Targeted Therapy	Yesika Simbolon	Atmajaya University	Australia
A-0134	PE1-16	Genetic Analysis of Compositions For Diagnosing Lung Cancer Comprising Peptide Nucleic Acid Probe Complementary To Lung Cancer Related Mutations	Ramlah Ramlah	Universitas Sulawesi Barat esia	Indonesia
A-0100	PE1-17	Spread Through Air Spaces in EGFR-mutated Lung Adenocarcinomas: Prevalence and Prognostic Significance	Yeon Bi Han	Seoul National University Bundang Hospital	Korea
A-0095	PE1-18	Decoding Alternative Splicing-Driven Immune Escape in Rare Lung Adenocarcinoma Subtypes Using Deep Learning and Minor Spliceosome Signatures	Rini Winarti	Yogyakarta State University	Indonesia
A-0081	PE1-19	Integrated Multi-Omics Profiling Identifies CEBPA as an Aging-Related Prognostic Biomarker in NSCLC	Jiaqi Zhu	Affiliated Hospital Of Nantong University	China
A-0038	PE1-20	Investigating the Role and Mechanisms of USP18-Mediated YAP Deubiquitination in Radiation-Induced Lung Injury	Haochun Guo	Zhongda Hospital, Medical School Of Southeast University	China
A-0037	PE1-21	Exploring the protection effects of Taxifolin on alleviating radiation-induced lung injury basing on USP18	Haochun Guo	Zhongda Hospital, Medical School Of Southeast University	China
A-0035	PE1-22	Comprehensive Analysis of Matrisome-Related Genes Reveals Prognostic Value and Immune Landscape in Lung Cancer	Hou Wang	Ningbo No.2 Hospital	China

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0096	PE1-23	A Peritumor-based Model Combining 3D Deep Learning and Radiomics for Preoperatively Predicting STAS in Invasive Lung Adenocarcinoma: a Multicenter Study	Xiaocui Liu	Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology	China
A-0244	PE1-24	Machine Learning Algorithms' Use in Plasma Biomarker-Based Lung Cancer Diagnosis	Siska Azizah	Baiturrahmah Universitya	Indonesia
A-0211	PE1-25	An AI-powered holotomography platform for predicting drug response in patient-derived lung cancer organoids	Mahn Jae Lee	Chungnam National University Hospital	Korea
A-0135	PE1-26	Development of Big Data for Predecting Lung Cancar (Study in Asia)	Rara Yulianda	Sulthan Thaha Saifuddin Islamic State University	Indonesia
A-0132	PE1-27	Enhancing using Artificial Intelligence in Detecting Lung Cancer in Asia	Rani Marsyanda	Sultan Thaha Saifuddin Islamic State University	Indonesia
A-0120	PE1-28	A Comprehensive Review of Legal and Ethical in the Implementation of AI & Big Data in Lung Cancer Diagnosis	Ferza Alfath	Alumnus Universitas Andalas	Indonesia
A-0119	PE1-29	AI-Driven Multi-Modal Prediction of Post-Surgical Recurrence in Brain-Metastatic Lung Adenocarcinoma: Integrating Tumor Dormancy, Stromal Remodeling, and TME Immune Exclusion Signals	Elfiany Syafruddin	Blk Muhammadiyah University	Indonesia
A-0075	PE1-30	Comparative Risk of Neurological Adverse Events Between PD-1 and PD-L1 Inhibitors in Korean Lung Cancer Patients: A Nationwide Cohort Study	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0067	PE1-31	Applying machine learning (ML) and artificial intelligence (AI) techniques to predict the risk of lung cancer in region of Chhattisgarh.	Manvendra Singh	Hmfa Miet	India

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0170	PE1-32	Assessment of the association between expression of Cyclin D1 protein with the clinicopathological characteristics and prognosis of lung cancer	Usha J Satanee	Nanduba Medical Center	India
A-0127	PE1-33	Trends of positive rates of initial screening and repeated screening in national organized population-based lung cancer screening in Korea	Nayoung Lee	National Cancer Center	Korea
A-0217	PE1-34	Economic Burden and Cost-Effectiveness of Lung Cancer Management in Indonesia: Evidence from Smoking-Attributable Mortality and EGFR-Targeted Therapies	Pisi Bethania Titalessy	Universitas Cenderawasih	Indonesia
A-0117	PE1-35	Highly Sensitive Digital Profiling of Tumor-derived Extracellular Vesicle RNA for EML4-ALK Mutations in Non-small Cell Lung Cancer	Beomseok Lee	Labspinner, Inc.	Korea
A-0173	PE1-36	Impact Evaluation of Cigarette Excise and Pricing on Smoking Habits and Lung Cancer Disease in Indonesia	Lintong Hottua Simbolon	The Pranala Institute	Indonesia

Scientific Program